1. Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B‐cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE‐170 phase 2 trial. (June 2017) Authors: Zinzani, P.; Thieblemont, C.; Melnichenko, V.; Osmanov, D.; Bouabdallah, K.; Walewski, J.; Majlis, A.; Fogliatto, L.; Caballero Barrigón, M.D.; Christian, B.; Gulbas, Z.; Özcan, M.; Salles, G.A.; Shipp, M.A.; Balakumaran, A.; Chlosta, S.; Chatterjee, A.; Armand, P. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 62 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗